1. Балаболкин М.И., Клебанова Е.М., Креминская В.М. Дифференциальная диагностика и лечение эндокринных заболеваний (руководство). М.: Медицина, 2002.
2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 6. Российская ассоциация эндокринологов. Под ред. И.И.Дедова, М.В.Шестаковой. М.: Информполиграф, 2013.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweigbt patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.
4. Agren JJ, Valve R, Vidgren H et al. Postprandial lipemic response is modified by the polymorphism at codon 54 of the acid-binding protein 2 gene. Arteriosiker. Thtomb Vasc Biol 1998; 18: 1606–11.
5. Betteridge DL. Lipid-lowering trials in diabetes. Curr Opin Lipidol 2001; 12 (6): 619–23.
6. Hayakawa T, Nagani Y, Nahara E et al. Variation of the fatty acid binding protein 2 gene is not associated with obesity and insulin resistance in Japanese subjectsэ. Metabolism 1999; 82: 655–9.
7. Hollenbeck C, Reaven GM. Variations in insulin stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 1987; 64: 1169–71.
8. Boden G, Cheung P, Stein TP et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol 2002; 283: E12–E19.
9. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–43.
10. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis Model Assessment (HOMA): insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–19.
11. Peterson DT, Reaven GM. Evidence that glucose load is an important determinant of plasma insulin response in normal subjects. Diabetes 1971; 20: 729–33.
12. Reaven GM. Effect of metformin on various aspects of glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus with varying degrees of hyperglycemia. Diab Metab Rev 1995; 11: S97–S108.
13. Salpeter SR, Greyber E, Pasternak GA, Saltpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analyse. Arch Intern Med 2003; 163 (21): 2594–602.
14. UK Prospective Diabetes Study Group. UK prospective diabetes study 16: overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–58.
15. Lissner L, Heitmann B. Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutrit 1995; 49: 79–90.
16. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update (PDF). Ann Intern Med 2002; 137 (1): 25–33.
17. Hundal R, Krssak M, Dufour S et al. Mechanism by which metformin reduces glucose production in type 2 diabetes (PDF). 2000. DiaDOI10.2337/diabetes.49.12.2063PMID 11118008
18. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100 (3): 328–41.
19. Schumann W, Petersen K, Landau B, Shulman G. Mechanism by which metformin reduces glucose production in type 2 diabetes (PDF). Diabetes 2000; 49 (12): 2063–9. DOI:10.2337/diabetes.49.12.2063. PMID 11118008
20. Kim YD, Park KG, Lee YS et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008; 57 (2): 306–14. DOI:10.2337/db07-0381
21. Dandona P, Weinstok R, Thusu S et al. Tumor necrosis factor-(in sera of obese patients fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907–20.
22. Jansen RC, Bogardus C, Takeda J et al. Linkage analysis of insulin secretion with GLUT 2 and glucokinase in Pima Indians and identification of a missense mutation in GLUT 2. Diabetes 1994; 43: 558–91.
23. Gerald M. Reaven. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not ? Diabetes Vasc Dis Res 2009; 6 (2): 133–8.
24. Wiernsperger N.F. Metformin: intrinsinc vasculoprotective properties. Diabetes Technol Tber 2000; 2: 259–72.
25. Ekstrom N, Schiwler I, Svensson AM et al. Effectivevss and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012; 2 (4).
26. Center for Drag Evaluation and Research. Guidance for industry diabetes mellitus evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes (Internet) 2008. Available from http://www.dagor/dawnloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ист071627.pdf en. 2012. Vol 2: e001076. Doi.10.1136
27. Мамедов М.Н., Косматова О.В. Опыт применения метформина у пациентов с метаболическим синдромом без сахарного диабета. Фарматека. 2006; 9.
28. Шилов А.М., Авшалумов А.Ш. и др. Коррекция факторов риска у пациентов с избыточной массой тела, сочетающейся с инсулинорезистентностью и артериальной гипертонией. Рус. мед. журн. 2011; 19 (13).

С.В.Подачина

ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России